Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus SULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus SULLA.
ILOSONE SULFA vs SULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
SULLA (sulfamethoxazole/trimethoprim) inhibits bacterial dihydropteroate synthase and dihydrofolate reductase, sequentially blocking folate synthesis and thereby nucleic acid production.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
100 mg orally once daily, increased to 200 mg daily if needed.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
6-12 hours; prolonged in renal impairment (up to 30 hours)
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Renal: 70-90% unchanged; biliary/fecal: 5-10%
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic